Mitigating Cancer's Impact: A Strategic Approach for Employers

Each year, American companies spend $1.5 billion on cancer treatment — and that’s in addition to the $139 billion lost to cancer-related absences and reduced productivity.1 Employers have the potential to curb these costs. Check out our white paper, Mitigating Cancer's Impact: A Strategic Approach for Employers, to learn about the best practices for driving employee cancer screenings.

Fill out the form below to download the research
Mitigating cancer impact

Fill out your details to get FREE access to the white paper now!

Additional details about this piece can be found above this form.

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Shockney L. Paying attention to cancer pays off for your employees [accessed 2024 Apr 18]. The Self-Insurer. 2017 Sep;107:36-40. https://www.johnshopkinssolutions.com/wpcontent/uploads/2017/10/SELF-INSURER-CANCER-AT-WORK.pdf